Role of taxane-based chemotherapy drugs may be underestimated, especially against prostate cancer, study suggests
Monday, September 17, 2012 - 17:00
in Health & Medicine
The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers. Most physicians and investigators believe that taxane chemotherapy (paclitaxel, docetaxel and cabazitaxel) just does one thing -- stop a cancer cell from dividing -- but the team of scientists has revealed it acts much more powerfully and broadly, especially against prostate cancer.